0.4316
Genprex Inc stock is traded at $0.4316, with a volume of 62.55M.
It is up +46.31% in the last 24 hours and up +24.02% over the past month.
See More
Previous Close:
$0.295
Open:
$0.32
24h Volume:
62.55M
Relative Volume:
18.50
Market Cap:
$3.67M
Revenue:
-
Net Income/Loss:
$-22.71M
P/E Ratio:
-0.0369
EPS:
-11.71
Net Cash Flow:
$-18.24M
1W Performance:
+26.20%
1M Performance:
+24.02%
6M Performance:
+30.79%
1Y Performance:
-86.12%
Genprex Inc Stock (GNPX) Company Profile
Name
Genprex Inc
Sector
Industry
Phone
512-537-7997
Address
1601 TRINITY STREET, BLDG. B, AUSTIN, TX
Compare GNPX with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
GNPX
Genprex Inc
|
0.4316 | 3.67M | 0 | -22.71M | -18.24M | -11.71 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 68.39B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Genprex Inc Stock (GNPX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jan-26-21 | Initiated | National Securities | Buy |
Apr-29-19 | Initiated | Noble Capital Markets | Outperform |
Genprex Inc Stock (GNPX) Latest News
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Genprex Delays Yearly Report Filing - TipRanks
Genprex Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Genprex, Inc. SEC 10-K Report - TradingView
Genprex (GNPX) Projected to Announce Earnings on Monday - Defense World
Genprex stock plunges to 52-week low of $0.27 - Investing.com
Genprex reports progress in lung cancer gene therapy By Investing.com - Investing.com South Africa
Genprex reports progress in lung cancer gene therapy - Investing.com India
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR Annual Meeting - PR Newswire
Genprex Collaborators Selected to Present Positive Preclinical Data on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions - Quantisnow
Game-Changing Gene Therapy Could End Daily Insulin Injections for Diabetes Patients - Stock Titan
Why Harrow Shares Are Trading Higher By 23%; Here Are 20 Stocks Moving Premarket - Benzinga
Genprex Collaborators Find NPRL2 Gene Therapy Using Oncoprex® De - GuruFocus.com
Genprex Inc (GNPX) Is On The Launchpad, Waiting For Long-Term Buyers. - Stocks Register
Genprex to Participate at BIO Europe Spring 2025 - StreetInsider.com
Can Genprex's Presence at BIO Europe Spring Attract New Partnership Opportunities? - Stock Titan
Genprex to Present at the 2020 LD Micro Virtual Conference - ACCESS Newswire
Genprex Strengthens Diabetes Focus with New License - TipRanks
Genprex explores non-viral gene therapy for diabetes By Investing.com - Investing.com Nigeria
Genprex Advances Diabetes Program With Addition Of Research Focused On Non-Viral Delivery System - Marketscreener.com
Genprex explores non-viral gene therapy for diabetes - Investing.com India
Can This New Delivery System Transform Diabetes Gene Therapy? Genprex's Latest Breakthrough - StockTitan
Genprex advances diabetes gene therapy with new license By Investing.com - Investing.com Nigeria
Genprex Provides Update On Diabetes Gene Therapy Program -February 18, 2025 at 10:03 am EST - Marketscreener.com
Genprex announces advancement of its diabetes gene therapy program - TipRanks
Genprex advances diabetes gene therapy with new license - Investing.com India
Genprex Provides Update on Diabetes Gene Therapy Program - Nasdaq
Genprex faces Nasdaq delisting over stock price, equity issues - MSN
Genprex Collaborators Find NPRL2 Gene Therapy Using Oncoprex® Delivery System is a Potential Treatment for Anti-PD1 Resistant Non-Small Cell Lung Cancer - BioSpace
Genprex's New Study Highlights NPRL2 Gene Therapy's Antitumor Activity In Lung Cancer - Nasdaq
Understanding GNPX’s financial ratios: A beginner’s guide - US Post News
Major Cancer Treatment Breakthrough: New Gene Therapy Defeats Drug-Resistant Lung Cancer - Stock Titan
Genprex faces Nasdaq delisting over stock price, equity issues By Investing.com - Investing.com Canada
Contrasting Genprex (NASDAQ:GNPX) & Avadel Pharmaceuticals (NASDAQ:AVDL) - Defense World
GNPX’s Market Whiplash: -38.94% YTD Decline, -42.28% Plunge in 30 Days - The InvestChronicle
Genprex Inc (NASDAQ: GNPX): An Enticing Stock To Watch - Stocks Register
Genprex doses first subject in expansion part of lung cancer gene therapy trial - Clinical Trials Arena
Genprex Announces First Patient Dosed in Phase 2 Expansion Portion of Acclaim-3 Clinical Study of Reqorsa® Gene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer - PR Newswire
Genprex, Inc. (NASDAQ: GNPX) Provides Updates on Oncology and Diabetes Programs - Defense World
Genprex Advances Cancer Trials and Diabetes Therapy - Yahoo Finance
Genprex to Participate at the 43rd Annual J.P. Morgan Healthcare Conference - BioSpace
SEC Form 424B5 filed by Genprex Inc. - Quantisnow
Genprex Inc Stock (GNPX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):